In Situ Hybridization Market Growth Drivers and Challenges:
Growth Drivers
- Presence of High-Quality Molecular Tests – In situ hybridization (ISH), a very potent molecular technique, that is used to diagnose certain chromosomal abnormalities by assessing the presence or absence of fluorescence-labeled signals in interphase or metaphase nuclei or chromosomes.
- Growing Elderly Population- The elderly population is more prone to age-related disorders such as cancer and other neurodegenerative diseases which is expected to drive the demand for in situ hybridization as this technology is widely used to study cancer, infectious diseases, and developmental biology, and can be used to detect cryptic chromosomal abnormalities and small aberrant clones.
According to the World Health Organization (WHO), the number of individuals in the world who are 60 or older will increase to 2.1 billion by 2050.
- Spiking Prevalence of Infectious Diseases- In situ hybridization (ISH) is a potent method for detecting specific RNAs and was created with the technology of molecular genetics to identify infectious pathogens.
- Increasing Trend of Minimally Invasive Procedures- The in situ hybridization (FISH) assay is a non-invasive method used to diagnose and track urothelial carcinoma (UC) in the upper urinary tract (UUT) and the test also looks for chromosomal alterations.
- Rising Advancements in Digital Pathology- Digital pathology is a branch of pathology that, will be used as a tool for FISH imaging in both clinical and research settings rather than live microscopy slides in the future.
Challenges
- Exorbitant Cost of In Situ Hybridization Assays- In situ hybridization is expensive owing to the use of the high cost of the specialized reagents, as well as the high cost of probes. Besides this, the technology is labor-intensive and consequently expensive for labs to utilize as it requires trained medical professionals and expertise.
- Lack of Skilled Professionals to Carryout In Situ Hybridization Diagnosis
- Growing Preference for Alternative Molecular Technologies Including Polymerase Chain Reaction (PCR)
In Situ Hybridization Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
7.3% |
|
Base Year Market Size (2025) |
USD 1.73 Billion |
|
Forecast Year Market Size (2035) |
USD 3.5 Billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of in situ hybridization is estimated at USD 1.84 Billion.
The global in situ hybridization market size was more than USD 1.73 Billion in 2025 and is anticipated to grow at a CAGR of over 7.3%, reaching USD 3.5 Billion revenue by 2035.
North America’s in situ hybridization market will dominate more than 45% share by 2035, fueled by rising healthcare spending and adoption of diagnostic technologies.
Key players in the market include Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited.
